Search results | gene therapy

Reports

Gene Therapy Partnering Terms and Agreements

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

Partnering Agreements with Seattle Genetics

The Partnering Agreements with Seattle Genetics report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Partnering Agreements with Regeneron Pharmaceuticals

The Partnering Agreements with Regeneron Pharmaceuticals report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

Partnering Agreements with Cangene

The Partnering Agreements with Cangene report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Genetic Disorders Partnering Terms and Agreements

The Genetic Disorders Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter genetic disorders partnering deals.

Regenerative Medicine Partnering Terms and Agreements

The Regenerative Medicine Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

Partnering Agreements with Celgene

This report provides all the information you require to better understand Celgene and its partnering interests and activities over the past seven years.

Partnering Agreements with Genentech

This report provides all the information you require to better understand Genentech and its partnering interests and activities over the past seven years.

Partnering Agreements with Pharmacyclics

The Partnering Agreements with Pharmacyclics report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Partnering Agreements with Jazz Pharmaceuticals

The Partnering Agreements with Jazz Pharmaceuticals report provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.

Insights

Gene therapy partnering

Gene therapy is the use of DNA as a pharmaceutical agent to treat disease

Aspen Pharmacare – Africa’s biggest generic drugmaker

Aspen Pharmacare specialises in the production of branded and generic pharmaceuticals and is currently the biggest pharmaceutical company in South Africa taking a 15% share of the total market.

Regenerative Medicine deal trends article

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Morphosys: Clear leaders in antibody generation

Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications.

Regenerative medicine: recent partnering deal trends

Regenerative medicine has become increasingly popular in recent years, with the number of deals announced growing steadily

Seattle Genetics: Empowering monoclonal antibodies

Seattle Genetics is a biotech company developing and commercializing antibody-based therapeutics to improve the lives of people living with cancer.

Seattle Genetics : Biotech industry partnering activity 2009-2014

Seattle Genetics, a successful big biotech industry headquartered in Seattle, focuses its effort on advancing antibody drug conjugate technology targeted toward cancer treatment.

Sun Pharmaceutical: Fast becoming the branded generic company of choice

Sun Pharmaceutical is a global specialty pharmaceutical company serving over 40 different markets with its brands and branded generics.

Regeneron Pharmaceuticals : Right technology, right time

Regeneron Pharmaceuticals is Biopharmaceutical Company focusing on the development of human antibody technologies for the treatment of a number of different diseases.

Regeneron Pharmaceuticals: Partnering activity 2009-2014

Regeneron Pharmaceuticals announced around 18 partnering / licensing deals since 2009.

Events

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Deals

BMS and UniQure in $1bn gene therapy pact

Agreement provides Bristol-Myers Squibb with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases

Genzyme and Voyager in $845 million AAV gene therapy pact

Voyager Therapeutics and Genzyme announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders

Genzyme in biotech deals with AskBio for gene therapy licensing

Genzyme biotech deals AskBio in a licensing agreement for duplex gene therapy vector technology.

Celgene announces pharma partnering with bluebird bio for gene therapy

bluebird bio announced the formation of a broad, global strategic pharma partnering with Celgene , a big pharma corporation, to discover, develop and commercialize novel disease-altering gene therapies in oncology.

GSK forms alliance with Fondazione Telethon and Fondazione San Raffaele to work on gene therapy for rare diseases

Pharmaceutical giant GlaxoSmithKline has signed a new alliance with two Italian organizations to research and develop new treatments for rare genetic disorders.

Development agreement for human regenerative therapy with induced pluripotent stem cells

Catalent Pharma Solutions announced an agreement with the Center for iPS Cell Research and Application at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans.

Pharma alliance between Regeneron and Bayer to develop combination therapy

Regeneron Pharmaceuticals and Bayer Healthcare form a pharma alliance to co-develop a potential combination therapy for $65.5 million.

Baxter pharma partners with Chatham Therapeutics for Hemophilia gene treatment therapy

Baxter International, a big pharma company has entered into an exclusive global pharma partners agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical for the development and commercialization of potential treatments for hemophilia B utilizing Chatham’s gene therapy technology

Morphogenesis signs agreement with Novartis to further development of cancer immunotherapy for companion animals

Through this agreement, Morphogenesis and Novartis will work closely together to advance the new platform technology to the companion animal market.

Celgene and AstraZeneca in MEDI4736 pact

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies